Function
Locations
Deficiency = MPS IVA (Morquio A syndrome).
Keratan sulfate and the galactose/N-acetylhexosamine termini of chondroitin, dermatan and keratan sulfate are degraded in the lysosome by an ordered exolytic cascade that complements the heparan-sulfate pathway. Keratan sulfate is a repeating -Gal-GlcNAc- polymer with 6-O- sulfates on both sugars: N-acetylgalactosamine-6-sulfatase / galactose-6-sulfatase (GALNS) removes the 6-O-sulfate from a terminal galactose-6-sulfate (and, in chondroitin-6-sulfate, from GalNAc-6-sulfate), and GlcNAc-6-sulfatase (GNS, in the heparan-sulfate module) removes it from GlcNAc-6-sulfate; lysosomal acid beta-galactosidase (GLB1) then hydrolyses the exposed terminal beta-galactose; and lysosomal beta-hexosaminidase — the alpha-beta heterodimer hexosaminidase A (HEXA+HEXB) and the beta-beta homodimer hexosaminidase B (HEXB) — removes the terminal beta-N-acetylhexosamine, regenerating a substrate for the next round. These enzymes are broadly specific: GLB1 also degrades the GM1 ganglioside, and hexosaminidase A (with the GM2-activator) degrades the GM2 ganglioside, so the same genes underlie both mucopolysaccharide and glycosphingolipid storage diseases. Disorders: MPS IVA (GALNS, Morquio A), GM1 gangliosidosis / MPS IVB (GLB1, Morquio B), Tay-Sachs (HEXA) and Sandhoff (HEXB) GM2 gangliosidoses.
All recommended fields populated.
✗ none found
No MODULE:keratan_chondroitin_sulfate_lysosomal_degradation deep-research report alongside the module YAML.
✓ every leaf node grounds to a representative protein.
✓ every declared conforms_to bundle matches its template motif.
4 complete review(s) · 0 with deep research · 0 missing review · 4 reviewed but lacking deep research
| Gene | Review | Complete | Deep research |
|---|---|---|---|
| GALNS P34059 | ✓ | ✓ | ✗ |
| GLB1 P16278 | ✓ | ✓ | ✗ |
| HEXA P06865 | ✓ | ✓ | ✗ |
| HEXB P07686 | ✓ | ✓ | ✗ |
Keratan/chondroitin sulfate lysosomal degradation, grounded to the human enzymes GALNS (UniProtKB:P34059, GO:0043890, EC 3.1.6.4), GLB1 (P16278, GO:0004565, EC 3.2.1.23) and the beta-hexosaminidase subunits HEXA (P06865) and HEXB (P07686) (both GO:0004563, EC 3.2.1.52; complex GO:1905379). GO molecular-function/BP/location terms were taken from the completed human gene reviews and verified against the local go.db; Reactome reaction ids/titles were verified against the local reactome cache. Each step uses a PANTHER family selector; the beta-hexosaminidase step is a PROTEIN_COMPLEX node (HEXA + HEXB, forming HexA alpha-beta and, for HEXB, HexB beta-beta). This is the sibling module to heparan-sulfate degradation: keratan sulfate is a -Gal-GlcNAc- polymer degraded by alternating desulfation (GALNS for Gal/GalNAc-6- sulfate, GNS for GlcNAc-6-sulfate — GNS reviewed in the heparan-sulfate module), beta- galactosidase (GLB1) and beta-hexosaminidase (HEXA/HEXB). The enzymes are broadly specific and also degrade gangliosides — GLB1 the GM1 ganglioside, hexosaminidase A the GM2 ganglioside — so the same genes cause both mucopolysaccharide (Morquio) and glycosphingolipid (GM1/GM2 gangliosidosis) storage diseases; GLB1/NEU1 act in a lysosomal multienzyme complex with CTSA. Disorders: MPS IVA (GALNS, Morquio A), GM1 gangliosidosis / MPS IVB (GLB1, Morquio B), Tay-Sachs (HEXA) and Sandhoff (HEXB). Chondroitin/dermatan sulfate degradation additionally uses ARSB (reviewed) and GUSB/IDS/IDUA (reviewed in the heparan-sulfate module).
Deficiency = MPS IVA (Morquio A syndrome).
Deficiency = GM1 gangliosidosis / MPS IVB (Morquio B).
Deficiency = Tay-Sachs disease (GM2 gangliosidosis type I).
Deficiency = Sandhoff disease (GM2 gangliosidosis type II; affects both HexA and HexB).